Minimally Invasive Uterine Fibroid Treatment is fastest growing...

Minimally Invasive Uterine Fibroid Treatment is fastest growing segment fueling growth of U.S. Uterine Fibroid Treatment Market

Posted 2023-11-14 08:59:34

Market key trends:
One of the key trends in the U.S. uterine fibroid treatment market is the rising adoption of minimally invasive treatment procedures such as uterine fibroid embolization and microwave thermotherapy. These procedures are associated with reduced treatment costs, lesser hospital stay and faster recovery time compared to hysterectomy. They utilize imaging guidance for precisely targeting and eliminating fibroids through catheter based delivery of embolic agents or heat energy. This has fueled their popularity among women aiming to preserve fertility.
Segment Analysis
The U.S. uterine fibroid treatment market is segmented based on treatment into embolization, medication, myomectomy (surgical removal of fibroids), hysterectomy (surgical removal of the uterus), and others. The embolization segment currently dominates the market owing to its minimally invasive nature and high success rate in removing uterine fibroids. Additionally, embolization has seen wider adoption compared to other treatments due to improved clinical success with fewer side effects and shorter recovery time.

Key Takeaways
The U.S. Uterine Fibroid Treatment Market Demand is expected to witness high growth, exhibiting CAGR of 4.0% over the forecast period, due to increasing prevalence of uterine fibroids and growing awareness regarding treatment.

Regional analysis
The Western region dominates the U.S. uterine fibroid treatment market currently owing to higher preference for minimally invasive treatments and presence of key players. California represents the fastest growing regional market.

Key players
Key players operating in the U.S. uterine fibroid treatment market are Blue Endo, Boston Scientific Corporation, CooperSurgical, Inc., Karl Storz SE & Co. KG, Myovant Sciences GmbH, Halt Medical, Inc., LiNA Medical ApS, Merit Medical Systems, Olympus Corporation, and Richard Wolf GmbH.